DS
KALV

DRW Securities’s KalVista Pharmaceuticals KALV Stock Holding History

DRW Securities’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,775
Closed -$196K – 1472
2025
Q3 		$196K Buy
+16,775
New +$232K ﹤0.01% 1092
2018
Q3 		– Sell
-20,600
Closed -$167K – 79
2018
Q2 		$167K Buy
20,600
+5,600
+37% +$49.4K 0.01% 77
2018
Q1 		$142K Buy
15,000
+3,000
+25% +$31.4K 0.01% 137
2017
Q4 		$117K Buy
+12,000
New +$125K 0.01% 430

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DRW Securities's KALV Position: Q4 2025 in Review

DRW Securities sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 16,775 shares — an estimated $196K sold.

DRW Securities first reported a position in KALV in Q4 2017 and held it in 4 quarters. The position peaked at $196K in Q3 2025. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • DRW Securities reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • DRW Securities sold 16,775 KalVista Pharmaceuticals shares in Q4 2025, an estimated $196K.
  • DRW Securities first reported a position in KalVista Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • DRW Securities's KalVista Pharmaceuticals position peaked at $196K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.